Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR.
Heinz AT, Schönstein A, Ebinger M, Fuchs J, Timmermann B, Seitz G, Vokuhl C, Münter M, Pajtler KW, Stegmaier S, von Kalle T, Kratz CP, Ljungman G, Juntti H, Klingebiel T, Koscielniak E, Sparber-Sauer M; Cooperative Weichteilsarkom Studiengruppe. Heinz AT, et al. Pediatr Blood Cancer. 2024 Jan;71(1):e30707. doi: 10.1002/pbc.30707. Epub 2023 Oct 9. Pediatr Blood Cancer. 2024. PMID: 37814424
BACKGROUND: Outcome of primary metastatic rhabdomyosarcoma (RMS) is poor. Certain risk factors as fusion status, Oberlin score, and local treatment of primary tumor are known to influence prognosis. ...RESULTS: In the European Soft Tissue Sarcoma Registry SoTiSaR (2009-201 …
BACKGROUND: Outcome of primary metastatic rhabdomyosarcoma (RMS) is poor. Certain risk factors as fusion status, Oberlin score, and l …
Treatment of nasolabial fold rhabdomyosarcoma in children: A single-institution experience.
Zhang G, Sun N, Ni X, Su Y, He L, Liu Z, Zhang J, Li Y, Zhang X, Liu Q, Liu Z, Li X, Mei L, Liu Y, Ji T, Wang S. Zhang G, et al. Head Neck. 2024 Apr;46(4):905-914. doi: 10.1002/hed.27637. Epub 2024 Jan 12. Head Neck. 2024. PMID: 38214480
RESULTS: Of 21 patients with nasolabial fold RMS, 90.48% were alveolar subtype, in which PAX3/7-FOXO1 fusion positive accounted for 87.5%. ...Almost all patients received comprehensive treatment (chemotherapy [100%], radiation therapy [100%], and surge …
RESULTS: Of 21 patients with nasolabial fold RMS, 90.48% were alveolar subtype, in which PAX3/7-FOXO1 fusion positive a …
NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.
Lai JP, Robbins PF, Raffeld M, Aung PP, Tsokos M, Rosenberg SA, Miettinen MM, Lee CC. Lai JP, et al. Mod Pathol. 2012 Jun;25(6):854-8. doi: 10.1038/modpathol.2012.31. Epub 2012 Mar 2. Mod Pathol. 2012. PMID: 22388761 Free PMC article.
A promising targeted therapy against NY-ESO-1 (CTAG 1B) using genetically modified T-cells in synovial sarcomas was recently demonstrated in a clinical trial at the NCI. To investigate the role of NY-ESO-1 immunohistochemistry in patient selection and gain better insight i …
A promising targeted therapy against NY-ESO-1 (CTAG 1B) using genetically modified T-cells in synovial sarcomas was recently demonstr …